WAYNE and MONTVILLE, N.J., May 7 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc., a U.S.-based pharmaceuticals unit of Bayer HealthCare, and Intendis Inc., a U.S.-based affiliate of Bayer Schering Pharma AG, Germany, announced today that they will jointly promote YAZ® (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement came into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of YAZ.
